Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients are required to have histologically or pathologically confirmed metastatic gastric or esophageal adenocarcinoma.~* Patients must demonstrate relapse or progression after at least one prior line of chemotherapy for metastatic disease.~* Patients must have measurable disease by CT scan or MRI~* Absolute neutrophil count ≥ 1,500/uL, platelet ≥ 100,000/uL and Hgb \> 8.0 g/dl.~* Total bilirubin ≤ upper institutional limit of normal (ULN), and AST or ALT ≤ 3x ULN; if liver metastases then AST or ALT \< 5x ULN~* Peripheral neuropathy must be ≤ Grade 1~* Creatinine \< 2 x ULN~* ECOG performance status 0 to 2~* Minimum life expectancy of 12 weeks.~* Age older than 18 years.~* Voluntary, signed written informed consent.~* Women of childbearing potential must have a negative pregnancy test Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.~Exclusion Criteria:~* History of severe hypersensitivity reaction to Cabazitaxel or other drugs formulated with polysorbate 80.~* Patients with known, untreated brain metastasis~* Any uncontrolled severe, intercurrent illness.~* Women who are breast-feeding.~* Patients who have undergone major surgery, chemotherapy, or radiotherapy within the last 3 weeks.~* Patients on concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- real drug (Type: EXPERIMENTAL): patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).